Association of thymidylate synthase polymorphisms with the tumor response to preoperative chemoradiotherapy in rectal cancer: a systematic review and meta-analysis

[1]  R. Beart,et al.  Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. , 2015, Journal of the National Cancer Institute.

[2]  E. Targarona,et al.  EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer , 2014, The Pharmacogenomics Journal.

[3]  P. Kienle,et al.  Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. , 2012, The Lancet. Oncology.

[4]  E. Targarona,et al.  Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. , 2011, International journal of radiation oncology, biology, physics.

[5]  Hoguen Kim,et al.  Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer. , 2011, International journal of radiation oncology, biology, physics.

[6]  R. Semrau,et al.  EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients , 2011, Clinical Cancer Research.

[7]  V. Canzonieri,et al.  Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy , 2011, The Pharmacogenomics Journal.

[8]  G. Spolverato,et al.  Predictive Factors of the Response of Rectal Cancer to Neoadjuvant Radiochemotherapy , 2011, Cancers.

[9]  C. Capirci,et al.  Patient-Reported Outcomes After Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Multicenter Prospective Observational Study , 2011, Annals of surgery.

[10]  Á. Carracedo,et al.  Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. , 2010, Pharmacogenomics.

[11]  Christophe Hennequin,et al.  Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Monill,et al.  Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil , 2010, Journal of Cancer Research and Clinical Oncology.

[13]  P. Conte,et al.  Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. , 2009, International journal of radiation oncology, biology, physics.

[14]  D. Aust,et al.  Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. , 2008, Cancer letters.

[15]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[16]  J. Lindebjerg,et al.  Germline Polymorphisms may Act as Predictors of Response to Preoperative Chemoradiation in Locally Advanced T3 Rectal Tumors , 2007, Diseases of the colon and rectum.

[17]  M. Agostini,et al.  A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation , 2006, Pharmacogenetics and genomics.

[18]  Bernard Leduc,et al.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Bosset.  Distal rectal cancer: sphincter-sparing is also a challenge for the radiation oncologist. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  C. Willett,et al.  Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[22]  H. Lenz,et al.  A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. , 2003, Cancer research.

[23]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[24]  A. Hinke,et al.  Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Ulrich,et al.  Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26]  W. Regine,et al.  Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. , 2000, International journal of radiation oncology, biology, physics.

[27]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[28]  N. Horie,et al.  Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. , 1995, Cell structure and function.

[29]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[30]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.

[31]  W. Enker,et al.  Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[33]  Á. Carracedo,et al.  X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. , 2012, International journal of radiation oncology, biology, physics.

[34]  S. Groshen,et al.  Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer , 2002, International Journal of Colorectal Disease.

[35]  S. Andreola,et al.  Pathological features of rectal cancer after preoperative radiochemotherapy , 1998, International Journal of Colorectal Disease.

[36]  B. Hirsch,et al.  Cancer Management and Research Dovepress Capecitabine in the Management of Colorectal Cancer , 2022 .